JP2022502066A5 - - Google Patents
Info
- Publication number
- JP2022502066A5 JP2022502066A5 JP2021519114A JP2021519114A JP2022502066A5 JP 2022502066 A5 JP2022502066 A5 JP 2022502066A5 JP 2021519114 A JP2021519114 A JP 2021519114A JP 2021519114 A JP2021519114 A JP 2021519114A JP 2022502066 A5 JP2022502066 A5 JP 2022502066A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- virus vector
- vector according
- scr4
- scr3
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816547.2A GB201816547D0 (en) | 2018-10-10 | 2018-10-10 | Oncolytic virus for the treatment of cancer |
| GB1816547.2 | 2018-10-10 | ||
| PCT/GB2019/052877 WO2020074902A1 (en) | 2018-10-10 | 2019-10-10 | Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502066A JP2022502066A (ja) | 2022-01-11 |
| JPWO2020074902A5 JPWO2020074902A5 (https=) | 2022-10-04 |
| JP2022502066A5 true JP2022502066A5 (https=) | 2022-10-04 |
| JP7410139B2 JP7410139B2 (ja) | 2024-01-09 |
Family
ID=64397608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519114A Active JP7410139B2 (ja) | 2018-10-10 | 2019-10-10 | 癌治療のための修飾ｂ５ｒ遺伝子を有する腫瘍溶解性ワクシニアウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12509704B2 (https=) |
| EP (1) | EP3863669A1 (https=) |
| JP (1) | JP7410139B2 (https=) |
| KR (1) | KR102937548B1 (https=) |
| CN (1) | CN113453713A (https=) |
| CA (1) | CA3123973A1 (https=) |
| GB (1) | GB201816547D0 (https=) |
| WO (1) | WO2020074902A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250044313A (ko) * | 2022-07-27 | 2025-03-31 | 아스트라제네카 아베 | Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5547862A (en) | 1993-07-29 | 1996-08-20 | Ambion Inc. | Vectors containing multiple promoters in the same orientation |
| FR2757178B1 (fr) | 1996-12-13 | 1999-03-05 | Centre Nat Rech Scient | Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament |
| US5955310A (en) | 1998-02-26 | 1999-09-21 | Novo Nordisk Biotech, Inc. | Methods for producing a polypeptide in a bacillus cell |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| KR100354441B1 (en) | 2000-12-27 | 2002-09-28 | Samsung Electronics Co Ltd | Method for fabricating spin-on-glass insulation layer of semiconductor device |
| CA2481304A1 (en) | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| AU2005222084B2 (en) | 2004-03-05 | 2010-04-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of RNAI agents |
| KR101772375B1 (ko) | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| BRPI0618441B8 (pt) | 2005-11-10 | 2021-07-27 | Genvec Inc | vetor adenoviral |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US20090196905A1 (en) | 2008-02-06 | 2009-08-06 | Spada Lon T | Stabilization of mitochondrial membranes in ocular diseases and conditions |
| CN101658670A (zh) | 2008-08-25 | 2010-03-03 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗 |
| ES2585242T3 (es) * | 2008-09-19 | 2016-10-04 | Etat Francais Représenté Par Le Directeur Central Du Service De Santé Des Armées | Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas |
| EP2199400A1 (en) | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| US20100291182A1 (en) | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| ES2362525B8 (es) | 2009-10-08 | 2013-01-03 | Azurebio, S.L. | Formulación de medicamentos en forma de agujas percutaneas penetrantes. |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| WO2011125469A1 (ja) | 2010-04-09 | 2011-10-13 | 国立大学法人東京大学 | マイクロrna制御組換えワクシニアウイルス及びその使用 |
| US20120271272A1 (en) | 2010-10-15 | 2012-10-25 | Iscience Interventional Corporation | Device for ocular access |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US9284588B2 (en) | 2010-12-16 | 2016-03-15 | Novozymes, Inc. | Promoters for expressing genes in a fungal cell |
| CN103110939A (zh) | 2012-10-23 | 2013-05-22 | 郑州大学 | 诱导肿瘤特异性免疫的疫苗及其应用 |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| WO2017014296A1 (ja) * | 2015-07-22 | 2017-01-26 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| US10888594B2 (en) * | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
-
2018
- 2018-10-10 GB GBGB1816547.2A patent/GB201816547D0/en not_active Ceased
-
2019
- 2019-10-10 JP JP2021519114A patent/JP7410139B2/ja active Active
- 2019-10-10 CN CN201980081698.5A patent/CN113453713A/zh active Pending
- 2019-10-10 CA CA3123973A patent/CA3123973A1/en active Pending
- 2019-10-10 KR KR1020217013839A patent/KR102937548B1/ko active Active
- 2019-10-10 US US17/284,169 patent/US12509704B2/en active Active
- 2019-10-10 WO PCT/GB2019/052877 patent/WO2020074902A1/en not_active Ceased
- 2019-10-10 EP EP19794623.9A patent/EP3863669A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Attermann et al. | Human endogenous retroviruses and their implication for immunotherapeutics of cancer | |
| KR101114784B1 (ko) | 아데노바이러스 벡터 백신 | |
| JP2006141398A5 (https=) | ||
| JP2020515640A5 (https=) | ||
| JP2025023916A5 (https=) | ||
| US8293252B2 (en) | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization | |
| JPWO2019173798A5 (https=) | ||
| JP2022502066A5 (https=) | ||
| Sanchez et al. | Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8 | |
| Lin et al. | DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity | |
| Molinelli et al. | Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways | |
| Lui et al. | Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor | |
| JPWO2020124274A5 (https=) | ||
| Ma et al. | Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells | |
| JPWO2020074902A5 (https=) | ||
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| WO2007119895A1 (en) | Anti-cancer compositions | |
| Rodríguez et al. | Immunotherapy of murine hepatocellular carcinoma by α-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression | |
| Xue et al. | Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes | |
| Montero et al. | Immune effects observed after the injection of plasmids coding for rainbow trout (Oncorhynchus mykiss) CK5B, CK6 and CK7A chemokines demonstrate their immunomodulatory capacity and reveal CK6 as a major interferon inducer | |
| WO2021092719A1 (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| TWI259206B (en) | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof | |
| JPWO2020188348A5 (https=) | ||
| JP2006525786A5 (https=) | ||
| Launois et al. | Different epitopes of the LACK protein are recognized by Vβ4 Vα8 CD4+ T cells in H-2b and H-2d mice susceptible to Leishmania major |